Verruciform Xanthomas in the Setting of COVID-19: A Case Series and Review of Other Conditions Associated With This Benign Cutaneous Neoplasm.

Verruciform xanthoma is a rare benign neoplasm that predominantly affects the oral mucosa but can also affect cutaneous sites on the face, trunk, extremities, and genitalia. It is usually identified in isolation; however, there are several known associations with other conditions. Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus that emerged in December 2019 and caused a worldwide pandemic. It primarily manifests as a respiratory illness although various associations and sequelae of COVID-19 are still being elucidated. The clinical and pathologic presentations of two cases of Verruciform xanthoma associated with documented COVID-19 infection at our institution after the start of lockdowns during the COVID-19 pandemic in 2020-2021 are described. In addition, we reviewed the literature for other infectious and non-infectious diseases associated with Verruciform xanthomas to see if there is any basis for a potential link between this rare benign neoplasm and novel viral infection.

Eosinophilic Fasciitis with Concurrent Necrobiotic Granulomatous Dermatitis Related to Checkpoint Inhibition Therapy.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics. However, loss of physiologic tolerance in few cases has triggered rare and novel immune-related adverse events (irAEs). Eosinophilic fasciitis, an infrequently reported diffuse scleroderma-like entity, has been associated with ICI therapy. We report a case of a patient with metastatic melanoma treated with nivolumab who developed eosinophilic fasciitis with concurrent granulomatous dermatitis and lymphadenitis, the latter of which mimicked melanoma recurrence radiographically. Furthermore, this patient had a severe presentation that subsequently proved to be treatment-resistant to both corticosteroid and steroid-sparing therapies. To our knowledge, eosinophilic fasciitis has not been reported concurrently with granulomatous dermatitis in literature. We provide a narrative of this case and a review of therapeutic approaches for severe or refractory irAEs. With the increasing popularity of ICI therapy, we believe it is essential for clinicians to identify novel irAEs and be aware of treatments as late recognition could prove fatal.